Evaxion Biotech A/S (EVAX) announced the expansion of its vaccine pipeline with the addition of EVX-B4, a novel vaccine candidate targeting Group A Streptococcus or GAS.
This new program is powered by the company's proprietary AI-Immunology platform.
Group A Streptococcus is responsible for hundreds of millions of infections globally each year, ranging from common illnesses like strep throat and scarlet fever to severe and life-threatening conditions such as rheumatic heart disease and necrotizing fasciitis. There is currently no approved preventive vaccine for GAS.
According to Evaxion, initial computational analysis confirms that its AI-Immunology technology can rapidly identify and validate novel vaccine targets, accelerating the preclinical development of EVX-B4.
The company aims to build a comprehensive preclinical data package to support future partnerships and out-licensing opportunities.
CSO Birgitte Rønø noted that GAS was prioritized due to its global health impact and lack of preventive options.
EVX-B4 becomes the fifth infectious disease vaccine candidate in Evaxion's pipeline, which also includes three cancer vaccine programs, furthering its strategic goal of building a partner-ready vaccine portfolio.
The decision to advance EVX-B4 aligns with Evaxion's 2025 R&D milestones and reinforces the commercial and medical urgency in addressing invasive and non-invasive GAS infections worldwide.
Currently, EVAX is trading at $2.40, down by 1.96 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.